Backenroth Samuel 4
4 · NeuBase Therapeutics, Inc. · Filed Jul 16, 2019
Insider Transaction Report
Form 4
Backenroth Samuel
CEO & VP of Bus. Development
Transactions
- Other
Employee stock option (right to buy)
2019-07-12+3,000→ 0 totalExercise: $10.14→ Common stock (3,000 underlying) - Award
Employee stock option (right to buy)
2019-07-12+772,923→ 772,923 totalExercise: $5.39Exp: 2029-07-12→ Common stock (772,923 underlying)
Footnotes (2)
- [F1]1/48th of the total shares subject to the option shall vest monthly over four years, provided that such vesting shall occur on a scheduled vesting date only if Mr. Backenroth's employment with the Company has not been terminated prior to such vesting date.
- [F2]Options to purchase common stock that were cancelled pursuant to the completion of the merger contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of January 2, 2019, by and among the Issuer (f/k/a Ohr Pharmaceutical, Inc.), Ohr Acquisition Corp., and NeuBase Therapeutics, Inc., as amended.